

## Anaesthesia recommendations for patients suffering from

### **Stüve-Wiedemann syndrome**

**Disease name:** Stüve-Wiedemann syndrome

**ICD 10:** Q78.8

**Synonyms:** (In older literature also known as Schwartz-Jampel type 2 syndrome)

Stüve-Wiedemann Syndrome (SWS) is an autosomal recessively inherited disorder characterized by congenital skeletal dysplasia, and life-threatening autonomic nerve dysfunction. SWS is caused by a mutation in the Leukemia Inhibitory Factor Receptor gene (LIFR;151443) on chromosome 5p13.1. SWS has been reported in different ethnic groups including Europeans, North Africans, Gypsies and Arabs. However, it seems to be particularly common in the United Arab Emirates.

Clinical characteristics of SWS include bowing of the long bones (bent-bone dysplasia), camptodactyly, deformities of joints and extremities, facial dysmorphism, hypotonia, growth retardation, and difficulties with feeding and swallowing.

The clinical course is generally complicated by unexpected hyperthermic episodes, respiratory insufficiency and feeding difficulties. Therefore it has a poor life expectancy and most patients die in early life.

---

Medicine in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnostic is wrong

---



Find more information on the disease, its centres of reference and patient organisations on Orphanet: [www.orpha.net](http://www.orpha.net)

---

SWS is caused by a mutation in the Leukemia Inhibitory Factor Receptor gene (LIFR;151443) on chromosome 5p13.1 [4]. It is particularly common in the United Arab Emirates population with a prevalence of 0.5/10,000 births. [5].

Clinical characteristics of SWS include bowing of the long bones (bent-bone dysplasia), hypertelorism, micrognathia, single transverse palmar crease, trismus, camptodactyly, deformities of joints and extremities, facial dysmorphism, hypotonia, growth retardation, and difficulties with feeding and swallowing [6,7]. Neurological features resemble dysautonomia with temperature instability, reduced pain sensation, and absent corneal reflexes; however, intellectual capabilities are normal.

The clinical course is generally complicated by unexpected hyperthermic episodes, respiratory insufficiency and feeding difficulties [7,8]. Therefore it has a poor life expectancy and most patients die in early life. SWS may also be associated with cardiovascular abnormalities, especially pulmonary hypertension due to arterial wall abnormality [9].

---

### **Typical surgery**

---

Orthopaedic (bone, joint and spine deformities) and eye surgery (cataract, corneal opacities).

There are a few other reports, as well as some theoretical risks, although the clinical significance of these are uncertain [20]. There is also a report of delayed tetraplegia after spinal surgery on two cases of SWS [22].

---

### **Type of anaesthesia**

---

Only one report of a 3-year-old child that received five times uneventful sevoflurane anaesthesia.

---

### **Necessary additional diagnostic procedures (preoperative)**

---

A thorough investigation of respiratory and cardiac function and reserves is mandatory. Several cardiac abnormalities have been noted in association with SWS [23], and if present in a patient, an anaesthetic experienced in cardiac anaesthesia would be ideal.

---

### **Particular preparation for airway management**

---

No specific deformities impairing airway management have been reported, but more difficult tracheal intubation may be anticipated. Plan a clinical pathway for induction of anaesthesia and prepare additional equipment for airway management and tracheal intubation.

---

### **Particular preparation for transfusion or administration of blood products**

---

Follow usual guidelines.

---

### Particular preparation for anticoagulation

---

Follow usual guidelines.

---

### Particular precautions for positioning, transport or mobilisation

---

Due to deformities of the extremities, positioning during anaesthesia should receive full attention.

---

### Probable interaction between anaesthetic agents and patient's long-term medication

---

No reported data available for SWS, but interactions are probable.

---

### Anaesthesiologic procedure

---

No particular anaesthetic agents are advised or contra-indicated, but extreme care with dosing of all drugs is essential.

---

### Particular or additional monitoring

---

Continuous temperature monitoring during the whole perioperative period.

Respiratory and haemodynamic monitoring are very important due to the vulnerability of SWS patients in these organ functions.

---

### Possible complications

---

Hyperthermic episodes	+
Respiratory insufficiency	+
Difficult airway/tracheal intubation	+
Haemodynamic disturbances	+
Pulmonary Aspiration	+
Abnormal response to NMBD's	?
Malignant hyperthermia susceptibility	+?

---

### **Postoperative care**

---

Observation in a PACU or ICU setting is strongly advised dependent on the preoperative problems and the course of surgery and anaesthesia.

---

### **Information about emergency-like situations / Differential diagnostics**

---

*caused by the illness to give a tool to distinguish between a side effect of the anaesthetic procedure and a manifestation of the diseases, e.g.:*

No information.

---

### **Ambulatory anaesthesia**

---

Not reported.

---

### **Obstetrical anaesthesia**

---

Never reported. Pregnancy not probable.

## Literature and internet links

1. Wiedemann HR, Stüve A. Stüve-Wiedemann syndrome, update and historical footnote. *Am J Med Genet* 1996;63:12-16
2. Cormier-Daire V, Geneviève D, Munnich A, Le Merrer M. New insights in congenital bowing of the femora. *Clin Genet* 2004;66:169-176
3. Nicole S, Davoine CS, Topaloglu H, Cattolico L, Barral D, et al. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). *Nat genet* 2000;26:480-3
4. Dagoneau N, Scheffer D, Huber C, et al. Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. *Am J Hum Genet* 2004;74:298-305
5. Akawi NA, Ali BR, Al-Gazali L. Stüve-Wiedemann syndrome and related bent bone dysplasias. *Clin Genet* 2012;82:12-21
6. Cormier-Daire V, Munnich A, Lyonnet S, et al. Presentation of six cases of Stuve-Wiedemann syndrome. *Pediatr Radiol* 1998;28:776-80
7. Mikelonis D, Jorczyk CL, Oxford JT. Stüve-Wiedemann syndrome: LIFR and associated cytokines in clinical course and etiology. *Orphanet J Rare Dis* 2014;9:34
8. Yeşil G, Lebre AS, Dos Santos S, Güran O, Ozahi Li, et al. Stuve-Wiedemann Syndrome: Is it underrecognized? *Am J Med Genetics* 2014;164A:2220-2205
9. Raas-Rotschild A, Ergaz-Schaltiel Z, Bar-Ziv J, Rein AJJT. Cardiovascular abnormalities associated with the Stuve-Wiedemann syndrome. *Am J Med Genetics* 2003;121A:156-58
10. Hassan A, Whately C, Letts M. The orthopedic manifestations and management of children with Stüve-Wiedemann syndrome. *J Bone Joint Surg* 2010;92:880-4
11. Bonthuis D, Morava E, Booij LHDJ, Driessen JJ. Stuve Wiedemann syndrome and related syndromes: case report and possible anesthetic complications. *Pediatr Anesthesia* 2009;19:212-17
12. Que T, Nishimoto M, Kitaura M, Samuta T, Toda N, Koyama V, Inoue K, Danura T. Anesthetic management of a child with Schwartz-Jampel syndrome. *Masui* 2004;53:782-4
13. Crisponi L, Crisponi G, Meloni A, et al. Crisponi syndrome is caused by mutations in the CRLF1 gene and is allelic to cold-induced sweating syndrome type I. *Am J Hum Genet* 2007;80:971-81
14. Dagoneau N, Bellais S, Blanchet P, et al. Mutations in Cytokine Receptor-like factor 1 (CRLF1) account for both Crisponi and cold-induced sweating syndromes. *Am J Hum Genet* 2007;80:966-970
15. Rigante D. Are there febrile diseases with a risk of sudden death in children? *Arch Dis Child* 2012;97:180
16. Morava E, Hamel B, Hol F, Rodenburg R, Smeitink J. Mitochondrial dysfunction in Stüve-Wiedemann syndrome in a patient carrying an ND1 gene mutation. *Am J Med Genet Part A* 2006;140A:2248-50
17. Chabrol B, Sigaudy S, Paquis V, Montfort M-F, Giudicelly H, et al. Stüve-Wiedemann syndrome and defects of the mitochondrial respiratory chain. *Am J med Gene* 1997;72:222-226
18. Seay AR, Ziter FA. Malignant hyperpyrexia in a patient with Schwarz-Jampel syndrome. *J Pediatr* 1978; 93:83-84
19. Fowler W, Layzer R, Taylor R, et al. The Schwartz-Jampel syndrome. Its clinical, physiological and histological expressions. *J Neurol Sci* 1974; 22:127-146
20. Bonthuis, D., E. Morava, L. H. Booij, J. J. Driessen. Stuve Wiedemann syndrome and related syndromes: case report and possible anesthetic complications. *Paediatr Anaesth* 2009;19(3):212-217
21. Langer, R., L. Al-Gazali, P. Raupp, E. Varady. Radiological manifestations of the skeleton, lungs and brain in Stueve-Wiedemann syndrome. *Australas Radiol* 2007;51(3):203-210.
22. Pizones, J., P. D. Sponseller, E. Izquierdo, E. Sanz, F. Sánchez-Mariscal, P. Álvarez, L. Zúñiga. Delayed Tetraplegia After Thoracolumbar Scoliosis Surgery in Stuve-Wiedemann Syndrome. *Spine Deformity* 2013;1(1):72-78
23. Raas-Rothschild, A., Z. Ergaz-Schaltiel, J. Bar-Ziv, A. J. Rein. Cardiovascular abnormalities associated with the Stuve-Wiedemann syndrome. *Am J Med Genet A* 2003;121A(2):156-158.

## Attachment 1 Relationship with other diseases

There is a clinical overlap between SWS and Crisponi syndrome, especially concerning the unexpected hyperthermic episodes. Both are caused by mutations of genes involved in the ciliary neurotrophic factor (CNTF)-receptor pathway. The Crisponi syndrome is caused by a mutation in the Cytokine Receptor-Like factor 1 (CRLF1) [13]. CRLF1 is involved in the CNTF-receptor-pathway where also the LIFR receptor is part of [14]. These diseases cause unprovoked episodic high temperature which reflect systemic release of cytokines. Recently it was hypothesized that those apparently unprovoked high temperatures may put the children at risk for sudden death [15].

When encountering a child with bowing of the long bones, one should also consider Campomelic Dysplasia, Schwartz-Jampel syndrome and Ehlers-Danlos type IX syndrome as possible causes [5,7]. SWS may also be associated with mitochondrial disorders by ND1 gene mutations, leading to impaired oxidative phosphorylation [16,17]. It is unclear whether this is coincidence or a true relationship.

In textbooks and other literature, the risk of malignant hyperthermia susceptibility (MHS) in association with SWS has been speculated. There have been two case-reports which mention this possibility, but both are not very specific and the hyperthermic episodes were actually in patients with Schwartz-Jampel syndrome 1. This was reported when the SWS was still considered identical to Schwartz-Jampel syndrome. One case-report dates from 1978 [18]. The patient of this report received atropine, ketamine, N<sub>2</sub>O/O<sub>2</sub> and curare. She developed a 1.5°C rise in temperature within 10 min and a mild increase of creatinine kinase (216 mU·ml<sup>-1</sup>). The procedure was cancelled, the patient recovered and went home the following day. No muscle biopsy and IVCT test were taken to establish the diagnosis. Remarkably, no MHS triggering agents were used. The other case dates from 1974 [19]. This patient received N<sub>2</sub>O/O<sub>2</sub> and halothane, during this procedure *'thermoregulatory control was disturbed resulting in a moderate hyperthermia'*. Also in this case the diagnosis MH could not be confirmed. Despite the confusion it should be realized that hyperthermic episodes are a hallmark of SWS and are the result of impairment of the ciliary neurotrophic factor receptor pathway without any relationship with the molecular or genetic background of MHS.

---

**Last date of modification: November 2015**

---

*This guideline has been prepared by:*

**Author**

**Jacques Driessen**, Anaesthesiologist, UMNC, Nijmegen, The Netherlands  
[jj.driessen@anes.umcn.nl](mailto:jj.driessen@anes.umcn.nl)

**Peer revision 1**

**Lihadh Al-Gazali**, Paediatrician, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates  
[l.algazali@uaeu.ac.ae](mailto:l.algazali@uaeu.ac.ae)

**Peer revision 2**

**Javier Pizones**, Spine Unit, Department of Orthopaedic Surgery, Hospital Universitario de Getafe, Madrid, Spain  
[javierpizones@gmail.com](mailto:javierpizones@gmail.com)

**Peer revision 3**

**Mallinath Chakraborty**, Department of Child Health, Cardiff University, Cardiff, UK  
[chakrabortym@cardiff.ac.uk](mailto:chakrabortym@cardiff.ac.uk)

---